论文部分内容阅读
PURPOSE: To assess the role of systemic non-steroidal antiinflammatory drugs (NSAIDs) in the treatment of inflammatory cystoid macular edema (iCME). DESIGN: Pilot study. METHODS: We included 66 patients with iCME and treated them with naproxen (2 × 250 mg daily; n=28) or rofecoxib (1 × 25 mg daily; n=38). After 4 months of therapy, visual acuity and in-flammation activity were measured. We evaluated the grade of CME, retinal vasculitis, and papillary leakage with fluorescein angiography. RESULTS: No clear effect of NSAIDs on iCME, visual acuity, and intraocular inflammation was observed. A beneficial effect was noted in less than 8% of the affected eyes. The drop-out rate after 4 months of treatment was 52% , because of adverse effects or inefficacy of the treatment. Improvement of visual acuity was slightly better in patients who were treated with naproxen compared with rofecoxib (P ≤ .05). CONCLUSION: Systemic NSAIDs have a limited role (if any) in the treatment of iCME.
PURPOSE: To assess the role of systemic non-steroidal antiinflammatory drugs (NSAIDs) in the treatment of inflammatory cystoid macular edema (iCME). METHODS: Pilot study. METHODS: We included 66 patients with iCME and treated them with naproxen (2 × 250 nal of 28) or rofecoxib (1 × 25 mg daily; n = 38). After 4 months of therapy, visual acuity and in-flammation activity were measured. We evaluated the grade of CME, retinal vasculitis, and papillary leakage with fluorescein angiography. RESULTS: No clear effect of NSAIDs on iCME, visual acuity, and intraocular inflammation was observed. A beneficial effect was noted in less than 8% of the affected eyes. The drop-out rate after 4 months of treatment was 52 Improvement of visual acuity was slightly better in patients who were treated with naproxen compared with rofecoxib (P ≤ .05). CONCLUSION: Systemic NSAIDs have a limited role (if any) in the treatment of iCME.